Chronic kidney disease (CKD), as well as dialysis itself, can lead to cardiovascular alterations such as atherosclerosis and left ventricular hypertrophy (LVH), the largest causes of death in haemodialysis patients.1 Fresenius Medical Care?s mission is to enable nephrologists to provide the best possible therapy for their long-term haemodialysis patients in order to minimise the risk of CVD. The central point of Cardioprotective Haemodialysis is haemodiafiltration. By achieving high subsitution volumes, HighVolumeHDF® therapy is credited with more effective elimination of middle molecules. With its numerous positive effects on cardiovascular risk factors, HighVolumeHDF® is currently considered as the most efficient renal replacement therapy.